Relapsed/Refractory B-cell Malignancies Clinical Trial
Official title:
A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Malignancy Activity of AC676 in Patients With Relapsed/Refractory B-cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: - Identify the recommended dose of AC676 that can be given safely to participants - Evaluate the safety profile of AC676 - Evaluate the pharmacokinetics of AC676 - Evaluate the effectiveness of AC676
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult male and female patients, at least 18 years-of-age at the time of signature of the informed consent form (ICF). 2. Patients with histologically confirmed relapsed/refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM). 3. Must have received at least 2 prior systemic therapies or have no other therapies to provide significant clinical benefit in the opinion of the Investigator or who are not amenable (intolerability, patient choice) to standard therapies. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from study entry: 1. Treatment with any of the following: - Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days). - Systemic chemotherapy within 14 days. - Radiation therapy within 14 days - Biologics (Antibodies) treatment within 28 days, - Radioimmunoconjugates or toxin conjugates within 12 weeks. - Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed. - Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD. 2. History of central nervous system lymphoma/leukemia in remission for less than 2 years. 3. Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator. |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University - The James Cancer Hospital and Solove Research Institute | Columbus | Ohio |
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
United States | Colorado Blood Cancer Institute | Denver | Colorado |
United States | Tennessee Oncology | Nashville | Tennessee |
United States | Florida Cancer Specialists | Sarasota | Florida |
United States | Swedish Cancer Institute | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Accutar Biotechnology Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of dose limiting toxicities (DLTs) from AC676 monotherapy | From cycle 1 day 1 to Cycle 1 day 28. Cycles are 28 days. | ||
Primary | Incidence of treatment-emergent adverse events (TEAEs) and clinically significant Grade 3 or higher laboratory abnormalities using CTCAE v5.0 criteria. | Approximately 18 months | ||
Primary | Maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) | Approximately 18 months | ||
Secondary | Pharmacokinetic Analysis: area under the plasma concentration-time curve over the dosing interval (AUC(0-inf)) | Up to approximately 20 weeks | ||
Secondary | Pharmacokinetic Analysis: area under the plasma concentration-time curve from over the dosing interval (AUC(0-tau)) | Up to approximately 20 weeks | ||
Secondary | Pharmacokinetic Analysis: maximum plasma concentration (Cmax) | Up to approximately 20 weeks | ||
Secondary | Pharmacokinetic Analysis: time to maximum plasma concentration (tmax) | Up to approximately 20 weeks | ||
Secondary | Pharmacokinetic Analysis: terminal elimination half-life (t1/2) | Up to approximately 20 weeks | ||
Secondary | Objective Response Rate (ORR) in patients receiving AC676 | Approximately 18 months | ||
Secondary | Duration of Response (DOR) in patients receiving AC676 | Approximately 18 months | ||
Secondary | Time to Response (TTR) in patients receiving AC676 | Approximately 18 months | ||
Secondary | Disease Control Rate (DCR) in patients receiving AC676 | Approximately 18 months | ||
Secondary | Progression Free Survival rate (PFS) in patients receiving AC676 | Approximately 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02457559 -
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT04943016 -
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04689308 -
This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04861779 -
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 |